Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec 13;8(3):172-6.
doi: 10.1038/nrneurol.2011.191.

Translational stem cell therapy for amyotrophic lateral sclerosis

Nicholas M Boulis  1 , Thais Federici, Jonathan D Glass, J Simon Lunn, Stacey A Sakowski, Eva L Feldman
Affiliations
Review

Translational stem cell therapy for amyotrophic lateral sclerosis

Nicholas M Boulis et al. Nat Rev Neurol. .

Abstract

Effective treatments are urgently needed for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the loss of motor neurons. In 2009, the FDA approved the first phase I safety trial of direct intraspinal transplantation of neural stem cells into patients with ALS, which is currently in progress. Stem cell technologies represent a promising approach for treating ALS, but several issues must be addressed when translating promising experimental ALS therapies to patients. This article highlights the key research that supports the use of stem cells as a therapy for ALS, and discusses the rationale behind and approach to the phase I trial. Completion of the trial could pave the way for continued advances in stem cell therapy for ALS and other neurodegenerative diseases.

PubMed Disclaimer

References

    1. J Comp Neurol. 2009 Jun 1;514(4):297-309 - PubMed
    1. Cell Transplant. 2011;20(8):1153-61 - PubMed
    1. Neurodegener Dis. 2007;4(6):431-42 - PubMed
    1. Regen Med. 2011 Mar;6(2):201-13 - PubMed
    1. Mol Ther. 2008 Dec;16(12):2002-10 - PubMed

Publication types

MeSH terms

Substances